



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

| | | | | | |
|-------|---|----|---|------------------------|----------------------|
| | | | | Complete if Known | |
| | | | | Application Number | 09/852,910 |
| | | | | Filing Date | May 11, 2001 |
| | | | | First Named Inventor | Annette GILCHRIST |
| | | | | Group Art Unit | 1639 |
| | | | | Examiner Name | Teresa D. Wessendorf |
| | | | | Confirmation No. | 4758 |
| | | | | Attorney Docket Number | 2661-101 |
| Sheet | 1 | of | 4 | | |

U.S. PATENT DOCUMENTS

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

T. O. J.

12/7/06



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

| | | | | | |
|--|---|----|---|--------------------------|----------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | <i>Complete if Known</i> | |
| | | | | Application Number | 09/852,910 |
| | | | | Filing Date | May 11, 2001 |
| | | | | First Named Inventor | Annette GILCHRIST |
| | | | | Group Art Unit | 1639 |
| | | | | Examiner Name | Teresa D. Wessendorf |
| | | | | Confirmation No. | 4758 |
| Sheet | 2 | of | 4 | Attorney Docket Number | 2661-101 |

FOREIGN PATENT DOCUMENTS

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

| | | | | | |
|---|------|---|------------------------|--------------------------|----------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT  | | | | <i>Complete if Known</i> | |
| | | | | Application Number | 09/852,910 |
| | | | | Filing Date | May 11, 2001 |
| | | | | First Named Inventor | Annette GILCHRIST |
| | | | | Group Art Unit | 1639 |
| | | | | Examiner Name | Teresa D. Wessendorf |
| Confirmation No. | 4758 | | | | |
| 3 | of | 4 | Attorney Docket Number | 2661-101 | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|--------------------|-----------------------|--|----------------|
| jlw | | Barker et al., "Constitutively Active 5-Hydroxytryptamine _{2c} Receptors Reveal Novel Inverse Agonist Activity of Receptor Ligands", J. Biol. Chem., 269(16):11687-11690, 1994. | |
| | | Bertin et al., "Functional Expression of the Human Serotonin 5-HT1A Receptor in <i>Escherichia coli</i> ", J. Biol. Chem., 267(12):8200-8206, 1992. | |
| | | Chidiac et al., "Inverse Agonist Activity of β-Adrenergic Antagonists", Mol. Pharmacol., 45:490-499, 1994. | |
| | | Costa and Herz, "Antagonists with negative intrinsic activity at δ opioid receptors coupled to GTP-binding proteins", Proc. Natl. Acad. Sci. USA, 86:7321-7325, 1989. | |
| | | Costa et al., "Drug Efficacy at Guanine Nucleotide-Binding Regulatory Protein-Linked Receptors: Thermodynamic Interpretation of Negative Antagonism and of Receptor Activity in the Absence of Ligand", Mol. Pharmacol., 41:549-560, 1992. | |
| | | Farfel et al., "The Expanding Spectrum of G Protein Diseases", New Engl. J. Med., 340(13): 1012-1020, 1999. | |
| | | Flanagan et al., "Advances in understanding gonadotrophin-releasing hormone receptor structure and ligand interactions", Rev. of Reprod., 2:113-120, 1997. | |
| | | Ford et al., "Molecular Basis for Interactions of G Protein βγ Subunits with Effectors", Science, 280:1271-1274, 1998. | |
| | | Gilchrist et al., "Gα COOH-Terminal Minigene Vectors Dissect Heterotrimeric G Protein Signaling", Protocols: Science's STKE, 118, 2002. (Abstract only) | |
| | | Greco et al. "Cancer Gene Therapy: 'Delivery, Delivery, Delivery'", Frontiers in Bioscience, 7:1516-1524, 2002. | |
| | | Gromoll et al., "Functional and clinical consequences of mutations in the FSH receptor", Mol. and Cell. Endocrinol., 125:177-182, 1996. | |
| | | Hasegawa et al. "Two Isoforms of the Prostaglandin E Receptor EP3 Subtype Different in Agonist-independent Constitutive Activity", J. Biol. Chem., 271(4):1857-1860, 1996. | |
| ✓ | | Inanobe et al., "Molecular cloning and characterization of a novel splicing variant of the Kir3.2 subunit predominantly expressed in mouse testis", J. Physiol., 521.1:19-30, 1999. | |

| | | | |
|--------------------|----------|-----------------|---------|
| Examiner Signature | T. D. J. | Date Considered | 12/7/06 |
|--------------------|----------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

| | | | | | |
|--|--|----------|----|----------------------|------------------------|
| | | | | Complete if Known | |
| | | | | Application Number | 09/852,910 |
| | | | | Filing Date | May 11, 2001 |
| | | | | First Named Inventor | Annette GILCHRIST |
| | | | | Group Art Unit | 1639 |
| | | | | Examiner Name | Teresa D. Wessendorf |
| | | | | Confirmation No. | 4758 |
| | | 4 | of | 4 | Attorney Docket Number |
| | | 2661-101 | | | |



| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|-----------------------|--|-----------------|---------|--|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | | | |
| T ² | | | | | |
| J.D.W. | | Leeb-Lundberg et al., "Antagonists of Bradykinin That Stabilize a G-protein-uncoupled State of the B2 Receptor Act as Inverse Agonists in Rat Myometrial Cells", J. Biol. Chem., 269(42):25970-25973, 1994. | | | |
| | | Lewin, B., "G proteins may activate or inhibit target proteins," Genes VII, Oxford University Press 2000, Chapter 26, pages 809-811. | | | |
| | | Lipinski et al., "Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings", Adv. Drug Delivery Rev., 23:3-25, 1997. | | | |
| | | Matsuoka et al., "Sequence analysis of cDNA and genomic DNA for a putative pertussis toxin-insensitive guanine nucleotide-bindings regulatory protein α subunit", Proc. Natl. Acad. Sci. USA, 85:5384-5388, 1988. | | | |
| | | Nielsen et al., "Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide", Science, 254(5037):1497-1500, 1991. (Abstract only) | | | |
| | | Pei et al., "A constitutively active mutant β_2 -adrenergic receptor is constitutively desensitized and phosphorylated", Proc. Natl. Acad. Sci. USA, 91:2699-2702, 1994. | | | |
| | | Ren et al., "Constitutively Active Mutants of the α_2 -Adrenergic Receptor", J. Biol. Chem., 268(22):16483-16487, 1993. | | | |
| | | Samama et al., "Negative Antagonists Promote an Inactive Conformation of the β_2 -Adrenergic Receptor", Mol. Pharmacol., 45:390-394, 1994. | | | |
| | | Tiberi and Caron, "High Agonist-independent Activity Is a Distinguishing Feature of the Dopamine D1B Receptor Subtype", J. Biol. Chem., 269(45):27925-27931, 1994. | | | |
| | | Vanhauwe et al., "Thrombin Receptors Activate G_o Proteins in Endothelial Cells to Regulate Intracellular Calcium and Cell Shape Changes", J. Biol. Chem., 277(37):34143-34149, 2002. | | | |
| | | Vassart et al., "The G Protein-coupled Receptor Family and One of Its Members, the TSH Receptor ^{2a} ", Ann. N.Y. Acad. Sci., 766:23-30, 1995. | | | |
| | | | | | |
| | | | | | |
| Examiner Signature | J.D.W. | | Date Considered | 12/7/06 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.